Showing results (1-10 of 1,184) with videos related to
Sort By:
Pageof 119
Annual Review of Pharmacology and Toxicology|June 3, 2000
Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefitsC FlexnerAmerican Family Physician|June 24, 1998
Combination antiretroviral therapy for HIV infectionJ Maenza, C FlexnerClinical Pharmacology and Therapeutics|April 20, 2013
HIV cure: knocking on the doorC M Durand, C FlexnerNature|November 19, 1987
Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expressionC Flexner, A Hügin, B MossCellular Immunology|December 1, 1993
Clearance of recombinant vaccinia virus expressing IL-2: role of local host immune responsesA W Hügin, C Flexner, B MossVaccine|April 1, 1988
Roles of vaccinia virus in the development of new vaccinesB Moss, T R Fuerst, C Flexner, et al.Vaccine|February 1, 1990
Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2C Flexner, B Moss, W T London, et al.The Journal of Biological Chemistry|October 6, 2000
Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitorsP Dowell, C Flexner, P O Kwiterovich, et al.Virology|October 1, 1988
Characterization of human immunodeficiency virus gag/pol gene products expressed by recombinant vaccinia virusesC Flexner, S S Broyles, P Earl, et al.Antimicrobial Agents and Chemotherapy|April 19, 2000
Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitorsR R Speck, C Flexner, C J Tian, et al.Pageof 119